By Denny Jacob
BeiGene's Tevimbra gets a highly sought after recommendation.
The oncology company said the European Medicines Agency's Committee for Medicinal Products for Human Use $(CHMP)$ issued a positive opinion of its treatment in combination with gemcitabine and cisplatin for adults with recurrent, not amenable to curative surgery or radiotherapy, or metastatic nasopharyngeal cancer.
Nasopharyngeal cancer is a type of head and neck cancer that starts in the upper throat passage that connects the nose to the lungs.
Mark Lanasa, chief medical officer, solid tumors at BeiGene, said the announcement marks a second positive CHMP opinion for Tevimbra this year.
Tevimbra is currently approved in the European Union as a first-line treatment for eligible patients with gastric or gastroesophageal junction adenocarcinoma, among other use cases.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
May 27, 2025 07:12 ET (11:12 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。